rs2277892
Positions:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_022773.4(LMF1):c.540G>A(p.Thr180=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.132 in 1,611,352 control chromosomes in the GnomAD database, including 18,712 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.20 ( 4241 hom., cov: 32)
Exomes 𝑓: 0.12 ( 14471 hom. )
Consequence
LMF1
NM_022773.4 synonymous
NM_022773.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -3.63
Genes affected
LMF1 (HGNC:14154): (lipase maturation factor 1) Involved in triglyceride metabolic process. Predicted to be integral component of membrane. Predicted to be active in endoplasmic reticulum membrane. Implicated in familial lipase maturation factor 1 deficiency. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.72).
BP6
Variant 16-911054-C-T is Benign according to our data. Variant chr16-911054-C-T is described in ClinVar as [Benign]. Clinvar id is 1247993.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-911054-C-T is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-3.63 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.372 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LMF1 | NM_022773.4 | c.540G>A | p.Thr180= | synonymous_variant | 4/11 | ENST00000262301.16 | NP_073610.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LMF1 | ENST00000262301.16 | c.540G>A | p.Thr180= | synonymous_variant | 4/11 | 5 | NM_022773.4 | ENSP00000262301 | P1 |
Frequencies
GnomAD3 genomes AF: 0.200 AC: 30374AN: 151912Hom.: 4221 Cov.: 32
GnomAD3 genomes
AF:
AC:
30374
AN:
151912
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.168 AC: 41289AN: 245772Hom.: 4498 AF XY: 0.162 AC XY: 21604AN XY: 133694
GnomAD3 exomes
AF:
AC:
41289
AN:
245772
Hom.:
AF XY:
AC XY:
21604
AN XY:
133694
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.124 AC: 181604AN: 1459324Hom.: 14471 Cov.: 33 AF XY: 0.126 AC XY: 91474AN XY: 725868
GnomAD4 exome
AF:
AC:
181604
AN:
1459324
Hom.:
Cov.:
33
AF XY:
AC XY:
91474
AN XY:
725868
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.200 AC: 30440AN: 152028Hom.: 4241 Cov.: 32 AF XY: 0.199 AC XY: 14815AN XY: 74328
GnomAD4 genome
AF:
AC:
30440
AN:
152028
Hom.:
Cov.:
32
AF XY:
AC XY:
14815
AN XY:
74328
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
862
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Sep 21, 2018 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 03, 2019 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at